Literature DB >> 12719278

Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study.

Andreas Festa1, Ralph D'Agostino, Steven S Rich, Nancy S Jenny, Russell P Tracy, Steven M Haffner.   

Abstract

BACKGROUND: The 4G/5G polymorphism of the plasminogen activator inhibitor-1 (PAI-1) gene has been related to cardiovascular disease. METHODS AND
RESULTS: Insulin resistance was measured with a frequently sampled intravenous glucose tolerance test in the Insulin Resistance Atherosclerosis Study (IRAS), and PAI-1 4G/5G promoter genotype was established by allele-specific polymerase chain reaction amplification of genomic DNA. There were 287 subjects with the 4G/4G genotype (18.4%), 691 heterozygote subjects (44.2%), and 586 carriers of the 5G/5G genotype (37.5%). The genotype distribution was different across the 3 ethnic groups (P=0.001). PAI-1 levels were lower in blacks than in non-Hispanic whites and Hispanics and lower in non-Hispanic whites than in Hispanics (all P=0.0001). Subjects homozygous for the 4G allele had the highest plasma PAI-1, heterozygote subjects were intermediate, and 5G homozygotes had the lowest levels of PAI-1. These patterns remained unaffected by adjustments for age, gender, clinical center, glucose tolerance status, body mass index, waist, triglycerides, and insulin resistance. Multiple linear regression analyses showed that the 4G/5G genotype explained very little of the variation in PAI-1 levels (0.63% in non-Hispanic whites, 0.99% in Hispanics, and 2.37% in blacks), and interaction analyses revealed no significant differences in the relation of circulating PAI-1 levels to the 4G/5G genotype by ethnicity (P=0.4).
CONCLUSIONS: We have shown ethnic differences in the PAI-1 4G/5G polymorphism along with corresponding differences in circulating PAI-1 levels. The association of the genotype with PAI-1 levels was seen consistently among all 3 ethnic groups and was unaffected by metabolic covariates, including insulin resistance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12719278     DOI: 10.1161/01.CIR.0000066908.82782.3A

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  31 in total

1.  The determinants of plasma plasminogen activator inhibitor-1 levels differ for American and Japanese men aged 40-49.

Authors:  Tomoko Takamiya; Takashi Kadowaki; Wahid R Zaky; Hirotsugu Ueshima; Rhobert W Evans; Tomonori Okamura; Atsunori Kashiwagi; Yasuyuki Nakamura; Yoshiyuki Kita; Russell P Tracy; Lewis H Kuller; Akira Sekikawa
Journal:  Diabetes Res Clin Pract       Date:  2005-12-01       Impact factor: 5.602

2.  Pai-1 gene variants and COC use are associated with stroke risk: a case-control study in the Han Chinese women.

Authors:  Xiaoping Huang; Ying Li; Zhizheng Huang; Chun Wang; Zhenlin Xu
Journal:  J Mol Neurosci       Date:  2014-09-18       Impact factor: 3.444

3.  Association of elevated plasminogen activator inhibitor 1 levels with diminished lung function in patients with asthma.

Authors:  Seong Cho; Joseph Kang; Christopher Lyttle; Kathleen Harris; Brendan Daley; Leslie Grammer; Pedro Avila; Rajesh Kumar; Robert Schleimer
Journal:  Ann Allergy Asthma Immunol       Date:  2011-01-26       Impact factor: 6.347

4.  Promotor polymorphisms of plasminogen activator inhibitor-1 and other thrombophilic genotypes in cerebral venous thrombosis: a case-control study in adults.

Authors:  Marius Ringelstein; Alexander Jung; Klaus Berger; Monika Stoll; Katharina Madlener; Christof Klötzsch; Felix Schlachetzki; Erwin Stolz
Journal:  J Neurol       Date:  2012-04-12       Impact factor: 4.849

5.  4G/5G plasminogen activator inhibitor-1 polymorphisms and haplotypes are associated with pneumonia.

Authors:  Sachin Yende; Derek C Angus; Jingzhong Ding; Anne B Newman; John A Kellum; Rongling Li; Robert E Ferrell; Joseph Zmuda; Stephen B Kritchevsky; Tamara B Harris; Melissa Garcia; Kristine Yaffe; Richard G Wunderink
Journal:  Am J Respir Crit Care Med       Date:  2007-08-29       Impact factor: 21.405

6.  Male-female differences in the genetic regulation of t-PA and PAI-1 levels in a Ghanaian population.

Authors:  J A Schoenhard; F W Asselbergs; K A Poku; S A Stocki; S Gordon; D E Vaughan; N J Brown; J H Moore; Scott M Williams
Journal:  Hum Genet       Date:  2008-10-25       Impact factor: 4.132

7.  Soy isoflavones reduce asthma exacerbation in asthmatic patients with high PAI-1-producing genotypes.

Authors:  Seong H Cho; Ara Jo; Thomas Casale; Su J Jeong; Seung-Jae Hong; Joong K Cho; Janet T Holbrook; Rajesh Kumar; Lewis J Smith
Journal:  J Allergy Clin Immunol       Date:  2019-01-29       Impact factor: 10.793

8.  A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Authors:  Deborah French; Leo H Hamilton; Leonard A Mattano; Harland N Sather; Meenakshi Devidas; James B Nachman; Mary V Relling
Journal:  Blood       Date:  2008-02-19       Impact factor: 22.113

Review 9.  Association Between Plasminogen Activator Inhibitor-1 Genetic Polymorphisms and Stroke Susceptibility.

Authors:  Xin Hu; Xin Zan; Zhiyi Xie; Yunke Li; Sen Lin; Hao Li; Chao You
Journal:  Mol Neurobiol       Date:  2016-01-07       Impact factor: 5.590

10.  No association of the plasminogen activator inhibitor-1 promoter 4G/5G polymorphism with inhibitor level during basal transcription in vitro.

Authors:  Mei Zhan; Yuling Zhou; Zhong Chao Han
Journal:  Int J Hematol       Date:  2004-05       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.